Everolimus-d4 (Synonyms: RAD001-d4; SDZ-RAD-d4) |
Catalog No.GC47328 |
Everolimus-d4(RAD001-d4)는 Everolimus로 표시된 중수소입니다. Everolimus(RAD001)는 라파마이신 유도체이며 강력하고 선택적이고 경구 활성인 mTOR1 억제제입니다. Everolimus는 FKBP-12에 결합하여 면역억제 복합체를 생성합니다. Everolimus는 종양 세포 증식을 억제하고 세포 사멸과 자가포식을 유도합니다. Everolimus는 강력한 면역억제 및 항암 활성을 가지고 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1338452-54-2
Sample solution is provided at 25 µL, 10mM.
Everolimus-d4 is intended for use as an internal standard for the quantification of everolimus by GC- or LC-MS. Everolimus is a hydroxyethyl ether form of rapamycin that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM.1,2 It is orally available and shows improved pharmacokinetics and pharmacodynamics over rapamycin.2 Through its inhibition of mTOR, everolimus inhibits cell proliferation, metabolism, and angiogenesis in certain types of cancer.3,4 It also acts as an immunosuppressive agent in the context of organ transplantation.
1.Zeng, Z., Sarbassov, D.D., Samudio, I.J., et al.Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AMLBlood109(8)3509-3512(2007) 2.Lebwohl, D., Anak, Ö., Sahmoud, T., et al.Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseasesAnn. N.Y. Acad. Sci.129114-32(2013) 3.Yunokawa, M., Koizumi, F., Kitamura, Y., et al.Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cellsCancer Sci.103(9)1665-1671(2012) 4.Gurk-Turner, C., Manitpisitkul, W., and Cooper, M.A comprehensive review of everolimus clinical reports: A new mammalian target of rapamycin inhibitorTransplantation94(7)659-668(2012)
Average Rating: 5
(Based on Reviews and 13 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *